Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Abstract Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseli...

Full description

Bibliographic Details
Main Authors:	Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Hänel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00772-9

Similar Items

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
by: Niels Weinhold, et al.
Published: (2016-03-01)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
by: Dirk Hose, et al.
Published: (2019-06-01)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
by: S. Huhn, et al.
Published: (2022-06-01)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
by: Maximilian Merz, et al.
Published: (2017-08-01)

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
by: Hans Salwender, et al.
Published: (2024-12-01)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
by: Martina Emde-Rajaratnam, et al.
Published: (2023-11-01)

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
by: Maximilian Merz, et al.
Published: (2016-12-01)

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
by: Maximilian Merz, et al.
Published: (2018-01-01)

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
by: Maximilian Merz, et al.
Published: (2015-07-01)

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
by: Niels Weinhold, et al.
Published: (2021-06-01)

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
by: Mohamed H. S. Awwad, et al.
Published: (2018-10-01)

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
by: Kai Neben, et al.
Published: (2010-07-01)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
by: Cyrus Khandanpour, et al.
Published: (2021-10-01)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-01-01)

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
by: Dirk Hose, et al.
Published: (2011-01-01)

Novel immunotherapies in multiple myeloma – chances and challenges
by: Leo Rasche, et al.
Published: (2021-07-01)

The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
by: Christos Sachpekidis, et al.
Published: (2021-10-01)

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
by: Stephan M. Tirier, et al.
Published: (2021-11-01)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
by: Elias K. Mai, et al.
Published: (2024-11-01)

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
by: Martin Granzow, et al.
Published: (2017-07-01)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
by: Lukas John, et al.
Published: (2023-04-01)

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
by: E. K. Mai, et al.
Published: (2022-06-01)

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
by: Christof Scheid, et al.
Published: (2014-01-01)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
by: Anja Seckinger, et al.
Published: (2018-07-01)

Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma
by: Yasmeen Niazi, et al.
Published: (2022-12-01)

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
by: Jérôme Moreaux, et al.
Published: (2011-04-01)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
by: Joseph Kauer, et al.
Published: (2023-11-01)

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma
by: Elias K. Mai, et al.
Published: (2015-06-01)

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL
by: L. Leypoldt, et al.
Published: (2022-06-01)

Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma
by: Christos Sachpekidis, et al.
Published: (2019-09-01)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
by: Nicola Giesen, et al.
Published: (2022-01-01)

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma
by: Alboukadel Kassambara, et al.
Published: (2012-04-01)

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels
by: Pankaj Yadav, et al.
Published: (2018-04-01)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
by: Henk M. Lokhorst, et al.
Published: (2008-01-01)

P839: GAIN OF CHROMOSOME 1Q LEADS TO HIGH EXPRESSION OF SNORD78 AND ABERRANT RIBOSOME METHYLATION
by: Duoduo Zhao, et al.
Published: (2023-08-01)

Characterization of rare germline variants in familial multiple myeloma
by: Calogerina Catalano, et al.
Published: (2021-02-01)

Quantification of plasma cell dynamics using mathematical modelling
by: Marcel Mohr, et al.
Published: (2018-01-01)

The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level
by: Carolina Schinke, et al.
Published: (2023-06-01)

Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
by: Alboukadel Kassambara, et al.
Published: (2012-01-01)

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
by: Alboukadel Kassambara, et al.
Published: (2013-01-01)